Log in

NASDAQ:SCPHScpharmaceuticals Stock Price, Forecast & News

+0.32 (+4.13 %)
(As of 08/10/2020 04:00 PM ET)
Today's Range
Now: $8.07
50-Day Range
MA: $7.53
52-Week Range
Now: $8.07
Volume55,903 shs
Average Volume101,319 shs
Market Capitalization$169.55 million
P/E RatioN/A
Dividend YieldN/A
scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is Furoscix that consists of proprietary subcutaneous formulation of furosemide, which is delivered through the SmartDose drug delivery system for treatment of congestion in decompensated heart failure patients outside of the acute care setting. Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-negative organisms. The company has a development agreement with West Pharmaceutical Services, Inc. to incorporate SmartDose drug delivery system with Furoscix. The company was founded in 2013 and is headquartered in Burlington, Massachusetts.
Read More
Scpharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.2Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.93 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:SCPH



Sales & Book Value

Annual SalesN/A
Book Value$2.76 per share


Net Income$-33,000,000.00


Market Cap$169.55 million
Next Earnings Date8/12/2020 (Estimated)
OptionableNot Optionable
+0.32 (+4.13 %)
(As of 08/10/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SCPH News and Ratings via Email

Sign-up to receive the latest news and ratings for SCPH and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Scpharmaceuticals (NASDAQ:SCPH) Frequently Asked Questions

How has Scpharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Scpharmaceuticals' stock was trading at $7.77 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, SCPH stock has increased by 3.9% and is now trading at $8.07.
View which stocks have been most impacted by Coronavirus

Do Wall Street analysts recommend investors buy shares of Scpharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Scpharmaceuticals in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Scpharmaceuticals

When is Scpharmaceuticals' next earnings date?

Scpharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020.
View our earnings forecast for Scpharmaceuticals

How were Scpharmaceuticals' earnings last quarter?

Scpharmaceuticals Inc (NASDAQ:SCPH) announced its quarterly earnings data on Tuesday, May, 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.54) by $0.19.
View Scpharmaceuticals' earnings history

What price target have analysts set for SCPH?

3 brokerages have issued 12-month price targets for Scpharmaceuticals' stock. Their forecasts range from $10.00 to $15.00. On average, they anticipate Scpharmaceuticals' stock price to reach $13.00 in the next twelve months. This suggests a possible upside of 61.1% from the stock's current price.
View analysts' price targets for Scpharmaceuticals

Has Scpharmaceuticals been receiving favorable news coverage?

Headlines about SCPH stock have been trending positive on Tuesday, according to InfoTrie Sentiment. The research group rates the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Scpharmaceuticals earned a daily sentiment score of 2.8 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the immediate future.
View the latest news about Scpharmaceuticals

Are investors shorting Scpharmaceuticals?

Scpharmaceuticals saw a increase in short interest during the month of January. As of January 15th, there was short interest totaling 20,200 shares, an increase of 43.3% from the December 31st total of 14,100 shares. Based on an average daily volume of 45,900 shares, the days-to-cover ratio is currently 0.4 days. Approximately 0.2% of the shares of the stock are short sold.
View Scpharmaceuticals' Short Interest

Who are some of Scpharmaceuticals' key competitors?

What other stocks do shareholders of Scpharmaceuticals own?

Who are Scpharmaceuticals' key executives?

Scpharmaceuticals' management team includes the following people:
  • Mr. John H. Tucker, Pres, CEO, CFO & Director (Age 56)
  • Dr. Pieter Muntendam, Consultant (Age 61)
  • Ms. Rachael Nokes, Principal Accounting Officer
  • Katherine Taudvin, Director of Corp. Devel. & Investor Relations
  • Dr. John Mohr Pharm.D., Sr. VP of Clinical Devel. & Medical Affairs

When did Scpharmaceuticals IPO?

(SCPH) raised $96 million in an initial public offering (IPO) on Friday, November 17th 2017. The company issued 6,400,000 shares at a price of $14.00-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO.

What is Scpharmaceuticals' stock symbol?

Scpharmaceuticals trades on the NASDAQ under the ticker symbol "SCPH."

Who are Scpharmaceuticals' major shareholders?

Scpharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include 5AM Venture Management LLC (18.24%), Trexquant Investment LP (0.12%), Matisse Capital (0.08%) and New York State Common Retirement Fund (0.06%). Company insiders that own Scpharmaceuticals stock include Andrew J Schwab, John H Tucker, Ra Capital Healthcare Fund Lp and Ra Capital Management, LP.
View institutional ownership trends for Scpharmaceuticals

Which institutional investors are selling Scpharmaceuticals stock?

SCPH stock was sold by a variety of institutional investors in the last quarter, including Matisse Capital.
View insider buying and selling activity for Scpharmaceuticals

Which institutional investors are buying Scpharmaceuticals stock?

SCPH stock was acquired by a variety of institutional investors in the last quarter, including 5AM Venture Management LLC, New York State Common Retirement Fund, and Trexquant Investment LP. Company insiders that have bought Scpharmaceuticals stock in the last two years include Andrew J Schwab, John H Tucker, Ra Capital Healthcare Fund Lp, and Ra Capital Management, LP.
View insider buying and selling activity for Scpharmaceuticals

How do I buy shares of Scpharmaceuticals?

Shares of SCPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Scpharmaceuticals' stock price today?

One share of SCPH stock can currently be purchased for approximately $8.07.

How big of a company is Scpharmaceuticals?

Scpharmaceuticals has a market capitalization of $169.55 million. The company earns $-33,000,000.00 in net income (profit) each year or ($1.77) on an earnings per share basis. Scpharmaceuticals employs 21 workers across the globe.

What is Scpharmaceuticals' official website?

The official website for Scpharmaceuticals is www.scpharma.com.

How can I contact Scpharmaceuticals?

Scpharmaceuticals' mailing address is 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA, 01830. The company can be reached via phone at 617-517-0730 or via email at [email protected]

This page was last updated on 8/11/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.